News | Radiation Therapy | August 28, 2019

Xstrahl Launches SARRP Beamline for Pre-clinical Experiments

New pre-clinical radiation research and CT imaging platform can be used for photon, proton, carbon and flash experiments

Xstrahl Launches SARRP Beamline for Pre-clinical Experiments

August 28, 2019 — X-ray therapy systems developer Xstrahl announced the launch of the new SARRP (small animal radiation research platform) beamline pre-clinical radiation research and computed tomography (CT) imaging platform. The system was launched at the 2019 International Congress of Radiation Research (ICRR), Aug. 25-29 in Manchester, U.K.

Extendable with the Xstrahl MuriGlo, which the company calls the industry's first 3-D bioluminescent optical imaging modality, the new SARRP beamline enables researchers using beamline experiments to achieve high-quality images. The system uses onboard high-resolution cone-beam CT imaging and 3-D bioluminescent tomographic imaging to target micro beams (down to 0.5mm) to an accuracy of 200 µm. The SARRP allows the user to image the animal, contour the tumor/target and organs at risk, evaluate the dose and deliver the desired treatment.

For more information: www.xstrahl.com

Related Content

Members of Congress from both sides of the aisle issued a series of oversight letters to the Centers for Medicare and Medicaid Services (CMS) in recent months to urge the Agency to adjust its proposed radiation oncology advanced alternative payment model (RO Model)

Image by whitfieldink from Pixabay

News | Radiation Oncology | November 13, 2019
November 13, 2019 — Members of Congress from both sides of the aisle issued a series of oversight letters to the...
Bladder Abdomen Pelvis image with DLCExpert
News | Artificial Intelligence | November 07, 2019
November 7, 2019 — Mirada Medical, a global leader in...
Liver cancer tumor scanning using an MRI
News | Proton Therapy | November 04, 2019
November 4, 2019 – Two new studies support and inform the use of proton radiation therapy to treat patients with hepa
Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Feature | ASTRO | October 30, 2019 | By Greg Freiherr
At the American Society for Radiation Oncology’s (ASTRO) 2019 a
Advanced Radiation Therapy Upgrades AccuBoost Digital Brachytherapy Platform
News | Brachytherapy Systems, Women's Healthcare | October 23, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago, Advanced Radiation...
MD Anderson and Varian Partner to Optimize Radiation Oncology Treatment
News | Treatment Planning | October 18, 2019
The University of Texas MD Anderson Cancer Center and Varian announced a new strategic collaboration to develop an...
Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Feature | Prostate Cancer | October 16, 2019 | By Jeff Zagoudis
Radiation therapy is an important tool in the clinician’s armamentarium for treatment of localized, early-stage prost